Juanita Crook, MD, on Prostate Cancer: Results From an NRG/RTOG Brachytherapy Trial
2017 ASTRO Annual Meeting
Juanita Crook, MD, of the University of British Columbia, discusses late toxicity findings on transperineal ultrasound–guided brachytherapy for locally recurrent prostate cancer after external-beam radiation therapy (Abstract 1).
Bhishamjit S. Chera, MD, of the University of North Carolina, discusses quantification of human papillomavirus 16 in circulating tumor DNA during de-intensified chemoradiation therapy for favorable-risk HPV-associated oropharyngeal squamous cell carcinoma (Presentation 92).
Christopher R. Kelsey, MD, of Duke University Medical Center, discusses reducing the radiation dose from 30 Gy to 20 Gy for patients with diffuse large B-cell lymphoma. Phase II findings show this approach may be effective in light of improved systemic treatment and better chemotherapy response assessment (Presentation 298).
William A. Hall, MD, of the Medical College of Wisconsin, discusses trial findings on androgen deprivation and radiation alone, compared with androgen deprivation, radiotherapy, and surgery in men with high-risk, nonmetastatic adenocarcinoma of the prostate (Abstract 15).
Tamim Niazi, MDCM, of McGill University, discusses phase III study findings on hypofractionated, dose-escalation radiation therapy for high-risk adenocarcinoma of the prostate (Abstract 281).
Shulian Wang, MD, of the National Cancer Center in Beijing, and Benjamin Movsas, MD, of the Henry Ford Health System, discuss study results on the use of hypofractionated radiation therapy after mastectomy for the treatment of high-risk breast cancer (Abstract PL01).